MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. This unique mechanism targets key metabolic pathways involved in appetite regulation, insulin sensitivity, and weight management.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same class has impressed in a recent phase 2 clinical trial – and it only needs to be taken once a month.

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes,